The RSA Group has partnered with Neuro-Bio, a UK-based early stage biopharmaceutical company focusing on neurodegenerative diseases,  to secure the appointment of Dr. Robert Haigh as Chief Operating Officer.

Commenting on the appointment, Mark Howard, Partner at The RSA Group said, “We are delighted that we have been able to assist with this pivotal addition to Neuro-Bio’s leadership team as it continues with its quest to develop novel treatments for Alzheimer’s Disease.”

Read the full release here: 

Share this: